The vertical reality
For a cell or gene therapy company to gain approval for commercial launch means facing a manufacturing and financial transition that is more abrupt than in most other sectors of the life sciences. Clinical-stage manufacturing is typically low volume with a lot of documentation overhead per batch. Commercial launch requires reliable throughput, demand forecasting against real patient volume, and reimbursement and billing infrastructure that did not exist during the trial phase.
When companies treat this as a purely operational transition without re-evaluating the underlying financial system, they often find their NetSuite configuration for the clinical stage, built around low-volume trial supply, can’t support commercial-scale demand planning or the complexity of payer billing that comes with approval.
How NetSuite can help
Netsuite is scalable from clinical to commercial manufacturing without a re-platform, but the configuration needs to be revisited at the transition point: demand planning tied to real patient enrollment data, billing and reimbursement workflows that did not exist pre-approval, and manufacturing capacity accounting that reflects commercial throughput expectations rather than trial-scale batch volume.
Organizations that plan for this transition ahead of BLA approval, rather than react to it after launch, avoid the scramble of reconfiguring core financial workflows while also managing the operational demands of a commercial launch.
Why Archer Insights
Archer Insights has experience with cell and gene therapy companies throughout the development lifecycle from IND through BLA and into commercial launch and understands the changes in the financial picture at each stage. This means that the NetSuite configuration set up in the clinical phase is created with the commercial transition in mind, rather than having to do a second implementation project once approval is granted.